Nasdaq
$1.47▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $238.9MShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 9.14Pre-market26.09.14 21:008-KKey event#●●●#●●●
Cabaletta Bio, Inc.Bullish
Cabaletta Bio raised approximately $128.2 million in aggregate gross proceeds through the exercise of 53,090,190 common stock warrants issued in June 2025, which expired on September 12, 2026. A total of 51,287,000 warrants were exercised from issuance through the expiration date, strengthening the company's cash position.…more
$1.47+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.13Pre-market26.08.13 20:3410-QEarnings
Cabaletta Bio, Inc.
Cabaletta Bio reported its Q2 2026 financial results, announcing an increase in the shares available under its 2025 Inducement Plan from 275,000 to 1,275,000. The company also extended its office lease in Philadelphia through November 15, 2027, and reported 169,545,445 shares of common stock outstanding as of August 7, 2026.…more
$1.47+0.00%vs prev closeView filingShare - 8.13Pre-market26.08.13 20:328-KKey event
Cabaletta Bio, Inc.
Cabaletta Bio (CABA) reported a net loss of $51.02 million for the second quarter of 2026, with $225.1 million in cash and investments as of June 30, sufficient to fund operations through mid-2027. The company remains on track to report registrational data for its lead candidate, rese-cel, in mid-2027, followed by a BLA submission in 2H27, and plans to initiate a registrational study for SSc-associated ILD in 4Q26.…more
$1.47+0.00%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5After-hours26.10.06 05:01#●●●#●●●
Cabaletta Bio Grants Inducement Stock Options to New Hires
Cabaletta Bio has granted stock options for a total of 385,000 shares to four newly hired non-executive employees as an employment inducement. This is a standard compensation practice for talent acquisition and has a neutral impact on the company's valuation.…more
$1.47+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.13Pre-market26.08.13 20:30
●●●●●●●● ●●●●● ●●●●●●
Cabaletta Bio reported positive clinical data for its autoimmune therapy 'rese-cel' and remains on track to submit a BLA in the second half of 2027. The company is also scaling up its manufacturing capabilities by adding ElevateBio as a new CDMO partner.…more
$1.47+0.00%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report